Credit Suisse’s Sonoma Pharmaceuticals SNOA Stock Holding History

Credit Suisse’s Portfolio SNOA Stock Details SNOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-13	Closed	-$40K	–	4830
2013 Q4	$40K	Buy	+13	New	+$34.6K	﹤0.01%	4539

Other funds holding SNOA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Credit Suisse's SNOA Position: Q1 2014 in Review

Credit Suisse sold out of Sonoma Pharmaceuticals (SNOA) in Q1 2014, closing a stake of 13 shares — an estimated $40K sold.

Credit Suisse first reported a position in SNOA in Q4 2013 and held it in 1 quarter. The position peaked at $40K in Q4 2013. 18 funds tracked by Wall St. Rank hold SNOA as of Q1 2014.

Credit Suisse reported no remaining Sonoma Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
Credit Suisse sold 13 Sonoma Pharmaceuticals shares in Q1 2014, an estimated $40K.
Credit Suisse first reported a position in Sonoma Pharmaceuticals in Q4 2013 and held it in 1 quarter.
Credit Suisse's Sonoma Pharmaceuticals position peaked at $40K in Q4 2013.
18 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q1 2014.

Based on Credit Suisse's 13F filing for Q1 2014, filed 15 May 2014.